|
Xencor Inc (NASDAQ: XNCR) |
|
Xencor Inc
XNCR's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Xencor Inc's sales fell
by -81.9 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 328
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.75 %
Xencor Inc net loss increased from $-24 millions, to $-46 millions in III. Quarter 2024,
• More on XNCR's Growth
|
|
Xencor Inc realized a net loss in trailing twelve months.
Xencor Inc realized cash reduction of $ -0.37 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
595.15 |
PE TTM
|
|
Company's Price to Sales ratio is at 14.46.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 4.88.
• More on XNCR's Valuation
|
|
|
|
|
Xencor Inc realized net loss in trailing twelve months.
Xencor Inc realized cash outflow of $ -0.37per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
595.15 |
PE TTM
|
|
Company's Price to Sales ratio is at 14.46.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 4.88.
Xencor Inc Price to Book Ratio is at 1.71 lower than Industry Avg. of 827.77. and higher than S&P 500 Avg. of 0.01
• More on XNCR's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com